NEW YORK, September 30, 2015 /PRNewswire/ --

ACI Association has initiated research coverage on the following equities: ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), VIVUS, Inc. (NASDAQ: VVUS), Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), MannKind Corporation (NASDAQ: MNKD), and Ovascience Inc. (NASDAQ: OVAS). On Tuesday, September 29, 2015, Nasdaq ended at 4,517.32, down 0.59%, Dow Jones advanced 0.30% to finish the day at 16,049.13, and the S&P closed at 1,884.09, up 0.12%. Register for your complimentary reports at the links given below.                    

 

ZIOPHARM Oncology Inc.    

ZIOPHARM Oncology Inc.'s stock edged lower by 3.07% to close Tuesday's session at USD 8.85. The company's shares oscillated between USD 8.67 and USD 9.94. The stock recorded a trading volume of 4.75 million shares, which was above its 50-day daily average volume of 3.49 million shares. Over the last three days ZIOPHARM Oncology Inc.'s shares have declined by 30.42% and in the past one week the stock has moved down 29.20%. On a compounded total return basis, the company stock has shown a negative return of 1.56% in the past one month. The stock is trading at a price to book ratio of 10.48 and price to sales ratio of 763.38. Sign up and read the free notes on ZIOP at: http://www.aciassociation.com/ZIOP.pdf  

 

Vivus Inc.      

The stock of Vivus Inc. lost 4.68% to close Tuesday's session at USD 1.63. The shares of the company moved in the range of USD 1.60 and USD 1.75. A trading volume of 4.35 million shares was recorded, which was greater than its 150-day daily average volume of 2.22 million shares. Over the last five days, Vivus Inc.'s shares have declined by 1.81% while in the past one month the stock has gained a momentum of 46.85%. The company has returned 41.74% in the past one month, on a compounded total return basis. The stock is trading at a price to book ratio of 8.19 and price to sales ratio of 1.53. Register for free on ACI Association and access the latest research on VVUS at:  http://www.aciassociation.com/VVUS.pdf  

 

Keryx Biopharmaceuticals Inc.          

Keryx Biopharmaceuticals Inc.'s stock increased by 4.89% to close Tuesday's session at USD 3.54. The company's shares fluctuated in the range of USD 3.40 and USD 3.92. A total of 4.02 million shares exchanged hands, which surpassed its 50-day daily average volume of 2.08 million shares. Over the last three days Keryx Biopharmaceuticals Inc.'s shares have declined by 11.06% and in the past one week the stock has moved down 9.46%. Furthermore, over the last three months the stock has lost 64.53%. The stock is at a price to book ratio of 2.53 and price to sales ratio of 82.48. The complete research on KERX is available for free at:  http://www.aciassociation.com/KERX.pdf  

 

Mannkind Corp.        

Mannkind Corp's stock added 0.97% to close Tuesday's session at USD 3.12. The company's shares oscillated between USD 3.03 and USD 3.32. The stock recorded a trading volume of 3.90 million shares, which was below its 50-day daily average volume of 5.14 million shares. Over the last five days Mannkind Corp's shares have declined by 3.70% and in the past one month the stock has lost 20.20%. In addition, over the last three months the stock has lost 45.17% and year to date the shares have shed 40.17%. The stock is trading at a price to cash flow ratio of 17.86. Free in-depth research on MNKD is available at:  http://www.aciassociation.com/MNKD.pdf    

 

OvaScience Inc.       

OvaScience Inc.'s stock declined 40.98% to close Tuesday's session at USD 8.57. The share price vacillated between USD 8.35 and USD 10.68 marking a new 52-week low during the session. The stock recorded a trading volume of 3.83 million shares, which was above its 50-day daily average volume of 0.76 million shares and above its 52-week average volume of 0.62 million shares. Over the last three days OvaScience Inc.'s shares have declined by 52.52% and in the past one week the stock has moved down 54.41%. Moreover, in the last six months the stock has lost 75.32% and year to date the shares have shed 80.62%. On a compounded total return basis, the company has shown a negative return of 48.37% in the past one year. The complimentary notes on OVA Scan be downloaded in PDF format at:  http://www.aciassociation.com/OVAS.pdf  

 

About ACI Association: 

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein. The information in this release has been sourced from a third party data base.

NO WARRANTY 

ACI Association, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com/.

RESTRICTIONS 

ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE www.aciassociation.com

Copyright 2015 PR Newswire

MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more MannKind Charts.
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more MannKind Charts.